3149-00-6

Usage

Type of compound

Urea derivative

Structural components

Contains a butyl group and a phenylsulphonyl group

Common use

Drug or pharmaceutical intermediate

Therapeutic properties

Potential as an antihypertensive and diuretic agent

Applications

Managing conditions such as heart failure and hypertension

Additional potential

Anti-inflammatory and antineoplastic agent

Industry relevance

Valuable compound for pharmaceutical and medical industries

Chemical structure

Influences its properties and applications in the medical field

InChI:InChI=1/C11H16N2O3S/c1-2-3-9-12-11(14)13-17(15,16)10-7-5-4-6-8-10/h4-8H,2-3,9H2,1H3,(H2,12,13,14)

Upstream product

• 98-10-2 benzenesulfonamide 
• 41891-17-2 N-butylcarbamoyl chloride 
• 32111-09-4 Ethyl N-(Benzenesulphonyl)carbamate 
• 109-73-9 N-butylamine 
• 39078-72-3 S-methyl N-butylthiocarbamate 
• 111-36-4 n-butyl isocyanide 
• 1087391-80-7 benzenesulfonamide sodium salt 

Relevant academic research and scientific papers

Combinations comprising dipeptidylpeptidase-iv inhibitor

The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.

Synthesis of sulfonylurea derivatives used as oral antidiabetics by the selenium-assisted carbonylation using carbon monoxide with sulfur

Sulfonylurea derivatives including useful antidiabetics (Tolbutamide, Chlorpropamide) were synthesized in good yields from benzene-sulfonamides with thiocarbamates in the presence of DBU. Thiocarbamates were prepared by the selenium-assisted carbonylation

Lewis Acid Catalysed Preparation of some Carbamates and Sulphonylureas. Application to the Determination of Enantiomeric Purity of Chiral Alcohols

Lewis acids such as boron trifluoride-diethyl ether and aluminium chloride catalyze the reaction of alcohols and sulphonamides with isocyanates, affording carbamates and sulphonylureas, respectively, in acceptable yield.Applied to the formation of diastereoisomeric carbamates from chiral alcohols using Pirkle's reagents, , this technique provides a convenient method for determination of enantiomeric purity.